BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 19446546)

  • 1. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis.
    Donia M; Mijatovic S; Maksimovic-Ivanic D; Miljkovic D; Mangano K; Tumino S; Biondi A; Basile F; Al-Abed Y; Stosic-Grujicic S; Nicoletti F
    Eur J Pharmacol; 2009 Aug; 615(1-3):228-33. PubMed ID: 19446546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO.
    Mijatovic S; Maksimovic-Ivanic D; Timotijevic G; Miljkovic D; Donia M; Libra M; Coco M; McCubrey J; Al-Abed Y; Korac A; Stosic-Grujicic S; Nicoletti F
    Free Radic Biol Med; 2010 Apr; 48(8):1090-9. PubMed ID: 20114073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo.
    Maksimovic-Ivanic D; Mijatovic S; Harhaji L; Miljkovic D; Dabideen D; Fan Cheng K; Mangano K; Malaponte G; Al-Abed Y; Libra M; Garotta G; Nicoletti F; Stosic-Grujicic S
    Mol Cancer Ther; 2008 Mar; 7(3):510-20. PubMed ID: 18347138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
    Mojic M; Mijatovic S; Maksimovic-Ivanic D; Miljkovic D; Stosic-Grujicic S; Stankovic M; Mangano K; Travali S; Donia M; Fagone P; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
    Mol Pharmacol; 2012 Oct; 82(4):700-10. PubMed ID: 22798453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells.
    Mijatovic S; Maksimovic-Ivanic D; Mojic M; Malaponte G; Libra M; Cardile V; Miljkovic D; Harhaji L; Dabideen D; Cheng KF; Bevelacqua Y; Donia M; Garotta G; Al-Abed Y; Stosic-Grujicic S; Nicoletti F
    Nitric Oxide; 2008 Sep; 19(2):177-83. PubMed ID: 18460348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism.
    Nicoletti F; Di Marco R; Zaccone P; Salvaggio A; Magro G; Bendtzen K; Meroni P
    Hepatology; 2000 Oct; 32(4 Pt 1):728-33. PubMed ID: 11003616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts.
    Samsel L; Zaidel G; Drumgoole HM; Jelovac D; Drachenberg C; Rhee JG; Brodie AM; Bielawska A; Smyth MJ
    Prostate; 2004 Mar; 58(4):382-93. PubMed ID: 14968439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury.
    Mangano K; Lanteri R; Basile MS; Bellavia N; Latino R; Messina D; Fagone P; Colletti G; Nania R; Caltabiano R; Di Marco R; Di Cataldo A
    Int J Immunopathol Pharmacol; 2019; 33():2058738419862736. PubMed ID: 31298048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice.
    Stosic-Grujicic S; Cvetkovic I; Mangano K; Fresta M; Maksimovic-Ivanic D; Harhaji L; Popadic D; Momcilovic M; Miljkovic D; Kim J; Al-Abed Y; Nicoletti F
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1038-49. PubMed ID: 17148780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
    Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
    Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
    Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC
    Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
    Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
    Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
    Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
    Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
    Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE
    Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
    Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S
    Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.